Galaxy Diagnostics’ chief scientific officer, Edward B. Breitschwerdt, DVM, DACVIM and medical director, B. Robert Mozayeni, MD were among the speakers this past weekend at the International Lyme and Associated Diseases Society’s (ILADS’) Annual Conference.

Dr. Breitschwerdt’s presentation was titled Pathobiome of Blood and Complex Disease Expression: Lessons from Bartonellosis and Other Vector-Borne Infections. Dr. Mozayeni’s presentation was titled Essential Concepts in Lab Medicine and Text Interpretation in an Era of Molecular Diagnostics.

Galaxy Diagnostics offers advanced testing methods built from the unique scientific expertise our founders developed studying Bartonella species and treating Bartonella infections (Bartonellosis). Bartonella are bacteria transmitted by insects and arachnids, such as fleas and ticks, and cause symptoms that are similar to other tick-borne diseases. There is growing evidence that tick-borne disease, rather than adhering to the “one pathogen one disease” model, presents as a variety of symptoms driven by co-infections. Co-infection in tick-borne disease is when multiple species of bacteria or parasites are transmitted from a tick to the animal or human bitten.

This means a person that is infected with Borrelia burgdorferi, the bacteria that cause Lyme disease, could also be infected with Bartonella and other species of bacteria from a single tick bite. Testing for and successfully treating these concurrent infections presents unique challenges for physicians.

ILADS is a nonprofit, multidisciplinary medical society that is focused on improving diagnosis and treatment of these complex infections. The theme of this years conference was “Tick-Borne Diseases and the Immune System”.

To learn more about ILADS, its work, and how to get involved, you can visit their website here: https://www.ilads.org/

About Galaxy Diagnostics Inc.

As a social venture and a One Health company, Galaxy Diagnostics is passionate about protecting the animal-human bond through the surveillance, prevention and clinical management of flea-and tick-borne diseases shared by humans and animals. Not only do we offer the best molecular and serology test options available, but we work with researchers and clinicians to generate new knowledge about emerging infectious diseases such as bartonellosis, borreliosis and other vector-borne diseases. Based on our scientific expertise, we are able to provide counsel to clinicians and researchers dedicated to achieving the most accurate diagnosis possible for their patients. This central goal is reflected in our corporate values and everyday interaction with patients, clinicians and researchers.

Media Contact: James Rebenski

contact@galaxydx.com